More on CYTK
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $72.72 |
|
|||
| Open | $72.39 | ||||
| 52 Wk High | $13.18 | ||||
| 52 Wk Low | $6.00 | ||||
| Day High | $76.81 | ||||
| Day Low | $72.39 | ||||
| P/E | N/A | ||||
| EPS | $-1.24 | ||||
| Volume | 903,208 | ||||
- Truist Securities Reiterates Buy Rating on Cytokinetics (CYTK)
- Cytokinetics aficamten shows cardiac benefits in two HCM trial analyses
- Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
- Form 8-K CYTOKINETICS INC For: Aug 28
- Cytokinetics aficamten meets dual endpoints in non-obstructive HCM trial
- Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
- Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
- Form 4 CYTOKINETICS INC For: Aug 18 Filed by: Malik Fady Ibraham
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Form 8-K CYTOKINETICS INC For: Aug 13
Entities mentioned with CYTK
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- PDUFA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- AdCom | View Related Stories »
- Show More...
